Corporate Profile & Recent News

An organization
designed to innovate

ElevateBio is a Waltham-based technology-driven company powering transformative cell and gene therapies for the biopharma industry. It begins with an environment where scientific inventors can transform their visions for cell and gene therapies into reality for patients with devastating and life-threatening diseases. Working with leading biopharma and academic partners, ElevateBio's team of scientists, drug developers, and company builders are building an integrated ecosystem that is changing the face of cell and gene therapy and regenerative medicine.

News

& Media

Stay up-to-date with news from across the ElevateBio ecosystem.

Press Releases

ElevateBio Announces Presentation on Lentiviral Vector Platform at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 4, 2022
Read moreRead more

ElevateBio Announces Andrew Sandford Joins as President of ElevateBio BaseCamp

January 19, 2022
Read moreRead more

ElevateBio to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 6, 2022
Read moreRead more

ElevateBio Announces Issuance of U.S. Patent Providing Protection for RNA-Guided Nucleases Identified through its Life Edit Gene Editing Platform

November 15, 2021
Read moreRead more

ElevateBio Supercharges Gene Editing and Therapeutic Product Development Capabilities Through Acquisition of Life Edit Therapeutics

October 27, 2021
Read moreRead more

Boston Children’s Hospital and ElevateBio Announce Five-Year Cell and Gene Therapy Collaboration

June 29, 2021
Read moreRead more

ElevateBio Announces Margo Roberts, Ph.D. Joins as Scientific Advisor for Company’s Immunotherapy Platform Expansion

June 10, 2021
Read moreRead more

ElevateBio’s BaseCamp Selected as the 2021 Facility of the Year Award Category Winner for Operational Excellence by the International Society for Pharmaceutical Engineering

April 27, 2021
Read moreRead more

ElevateBio Announces Chief Scientific Officer of Regenerative Medicine, Melissa Carpenter, PhD, Elected to the International Society for Stem Cell Research Board of Directors

March 18, 2021
Read moreRead more

ElevateBio Scales Disruptive Cell and Gene Therapy Business Model with $525 Million Series C Financing

March 15, 2021
Read moreRead more

Executive Leaders and Co-Founders

Led and advised by a team of world-class biotech industry experts with unmatched track records in building iconic companies and creating value in the field of rare disease and cell and gene therapy
DAVID HALLAL
CEO & CHAIRMAN

David Hallal, Chairman and CEO of ElevateBio, is a 30-year veteran in the biopharmaceutical industry, with expertise in early-stage company building as well as operating large multinational biotech companies.

MITCHELL FINER, PH.D.,
President of Research and Development

Dr. Mitchell (Mitch) Finer, President of Research and Development at ElevateBio, has been instrumental in founding, building and leading a number of MPM portfolio companies. Mitch serves on several MPM portfolio company boards, including CODA, Oncorus, Semma Therapeutics and TCR2 Therapeutics.

vikas sinha
Chief financial officer

Vikas Sinha, CFO of ElevateBio, has more than 25 years of experience in executive finance roles in the life sciences industry. He previously served as the CFO of Alexion Pharmaceuticals. During his tenure as CFO, Alexion’s market cap grew from $600 million to more than $30 billion and revenue grew from zero to more than $3 billion.

Board of Directors

David Hallal, Co-Founder Chief Executive Officer & Chairman, ElevateBio
Mitchell Finer, Ph.D., President of Research and Development
Vikas Sinha, Chief Financial Officer
Ansbert Gadicke, M.D. Co-founder of MPM Capital
Morana Jovan-Embiricos, Ph.D., Managing Partner of F2 Ventures
Germano Giuliani, Former CEO, Giuliani Pharma; Board of Directors, HBM Healthcare AH; Investment Committee Royalty Pharma
Navneet Govil, Managing Partner, SoftBank
Karan Takhar, Managing Director, Matrix Capital Management Company

Investors committed to enabling
innovative cell and gene therapy companies